Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Cash from Operations (2016 - 2025)

Fennec Pharmaceuticals' Cash from Operations history spans 15 years, with the latest figure at 5962000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 304.48% year-over-year to 5962000.0, compared with a TTM value of 12473000.0 through Dec 2025, down 146.23%, and an annual FY2025 reading of 12473000.0, down 146.23% over the prior year.
  • Cash from Operations for Q4 2025 was 5962000.0 at Fennec Pharmaceuticals, down from 1493000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 39047000.0 in Q1 2024, with the low at 8387000.0 in Q2 2024.
  • Average Cash from Operations over 5 years is 1481166.67, with a median of 3639500.0 recorded in 2021.
  • Year-over-year, Cash from Operations skyrocketed 800.14% in 2024 and then tumbled 304.48% in 2025.
  • Tracing FENC's Cash from Operations over 5 years: stood at 2958000.0 in 2021, then tumbled by 129.95% to 6802000.0 in 2022, then increased by 28.55% to 4860000.0 in 2023, then skyrocketed by 69.67% to 1474000.0 in 2024, then tumbled by 304.48% to 5962000.0 in 2025.
  • Per Business Quant, the three most recent readings for FENC's Cash from Operations are 5962000.0 (Q4 2025), 1493000.0 (Q3 2025), and 3686000.0 (Q2 2025).